meai (5-methoxy-2-aminoindane or 5-meo-ai or chaperon) is a recreational drug and binge-drinking prevention drug, first chemically described in 1980, and first pharmacologically described in a peer reviewed paper in 2017 by david nutt et al., followed by another in february 2018 which detailed pharmacokinetics, pharmacodynamics and metabolism of meai. in 2018, a company in the united states began offering an meai-based drink called "pace".